Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,443 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.
Rizzieri DA, Crout C, Storms R, Golob J, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Lagoo AS, Morris A, Beaven A, Yang Y, Peterson B, Li Z, Chao NJ. Rizzieri DA, et al. Among authors: morris a. Cancer Invest. 2011 Jan;29(1):56-61. doi: 10.3109/07357907.2010.535055. Cancer Invest. 2011. PMID: 21166499 Free PMC article.
Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics.
Horwitz ME, Spasojevic I, Morris A, Telen M, Essell J, Gasparetto C, Sullivan K, Long G, Chute J, Chao N, Rizzieri D. Horwitz ME, et al. Among authors: morris a. Biol Blood Marrow Transplant. 2007 Dec;13(12):1422-6. doi: 10.1016/j.bbmt.2007.08.050. Biol Blood Marrow Transplant. 2007. PMID: 18022571 Free PMC article.
Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation.
Rizzieri DA, Storms R, Chen DF, Long G, Yang Y, Nikcevich DA, Gasparetto C, Horwitz M, Chute J, Sullivan K, Hennig T, Misra D, Apple C, Baker M, Morris A, Green PG, Hasselblad V, Chao NJ. Rizzieri DA, et al. Among authors: morris a. Biol Blood Marrow Transplant. 2010 Aug;16(8):1107-14. doi: 10.1016/j.bbmt.2010.02.018. Epub 2010 Feb 24. Biol Blood Marrow Transplant. 2010. PMID: 20188202 Free PMC article. Clinical Trial.
Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.
Crout CA, Koh LP, Gockerman JP, Moore JO, Decastro C, Long GD, Diehl L, Gasparetto C, Niedzwiecki D, Edwards J, Prosnitz L, Horwitz M, Chute J, Morris A, Davis P, Beaven A, Chao NJ, Ali-Osman F, Rizzieri DA. Crout CA, et al. Among authors: morris a. Cancer Invest. 2010 Jul;28(6):654-60. doi: 10.3109/07357901003631015. Cancer Invest. 2010. PMID: 20521909 Clinical Trial.
Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.
Kanda J, Rizzieri DA, Gasparetto C, Long GD, Chute JP, Sullivan KM, Morris A, Smith CA, Hogge DE, Nitta J, Song K, Niedzwiecki D, Chao NJ, Horwitz ME. Kanda J, et al. Among authors: morris a. Biol Blood Marrow Transplant. 2011 Jun;17(6):867-74. doi: 10.1016/j.bbmt.2010.09.009. Epub 2010 Sep 22. Biol Blood Marrow Transplant. 2011. PMID: 20868761 Free PMC article.
Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation.
Kanda J, Chiou LW, Szabolcs P, Sempowski GD, Rizzieri DA, Long GD, Sullivan KM, Gasparetto C, Chute JP, Morris A, McPherson J, Hale J, Livingston JA, Broadwater G, Niedzwiecki D, Chao NJ, Horwitz ME. Kanda J, et al. Among authors: morris a. Biol Blood Marrow Transplant. 2012 Nov;18(11):1664-1676.e1. doi: 10.1016/j.bbmt.2012.06.005. Epub 2012 Jun 12. Biol Blood Marrow Transplant. 2012. PMID: 22698485 Free PMC article.
Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry.
Spasojevic I, da Costa LR, Horwitz ME, Long GD, Sullivan KM, Chute JP, Gasparetto C, Morris A, Chao NJ, Rizzieri DA. Spasojevic I, et al. Among authors: morris a. Cancer Invest. 2012 Nov;30(9):679-82. doi: 10.3109/07357907.2012.726386. Epub 2012 Sep 28. Cancer Invest. 2012. PMID: 23020519 Free PMC article. No abstract available.
Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies.
Kanda J, Long GD, Gasparetto C, Horwitz ME, Sullivan KM, Chute JP, Morris A, Shafique M, Li Z, Chao NJ, Rizzieri DA. Kanda J, et al. Among authors: morris a. Biol Blood Marrow Transplant. 2014 Feb;20(2):257-63. doi: 10.1016/j.bbmt.2013.11.010. Epub 2013 Nov 20. Biol Blood Marrow Transplant. 2014. PMID: 24269380 Free PMC article.
5,443 results